Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 3 April 2009, doi:10.1136/bmj.b1234
Cite this as: BMJ 2009;338:b1234
Steven Doherty, associate professor, director , emergency consultant1,2
1 Rural Clinical School, University of Newcastle, Australia , 2 Locked Bag 9783, NEMSC, Tamworth, NSW 2348, Australia
Correspondence to: Steven.doherty@hnehealth.nsw.gov.au
Systemic corticosteroids reduce admission rates, relapse rates, and symptom duration and should be used for most acute exacerbations of acute asthma
| The first 150 words of the full text of this article appear below. |
Globally, 300 million people are estimated to have asthma, and the prevalence in most countries is increasing.1 Systematic reviews have found that systemic corticosteroids in acute asthma reduce admission rates, symptom duration, β agonist use, and repeat presentations for medical care.2 3 4 5 However, evidence exists that corticosteroids are underprescribed in acute asthma, with prescribing rates ranging from <60% for mild asthma to <85% for moderate and severe asthma across multiple sites.6 Systemic corticosteroids are recommended and should be prescribed, unless there are other contraindications, for all but the mildest of acute exacerbations of asthma.1
Meta-analyses have reviewed the role of corticosteroids in acute asthma.2 3 4 5 A meta-analysis of seven randomised controlled trials (426 admitted children aged 1-18 years) found that those who received systemic corticosteroids were discharged earlier (number needed to treat (NNT) 3) and were less likely to relapse within one to three months (odds ratio 0.19; 95% confidence interval 0.07
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses